Alnylam Pharma (ALNY) Misses Q2 EPS by 10c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $240.69 +1.51%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
RIBT, INLB, FTXP, More
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
RIBT, INLB, FTXP, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($0.85), $0.10 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $8.69 million versus the consensus estimate of $12.64 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
- BofA turns S&P 500 signals from red to yellow: What to buy now
- Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
